US 7,514,233 B2
	Integrase cofactor
Zeger Debyser, Heverlee (Belgium); Petr Cherepanov, Brookline, Mass. (US); and Erik De Clercq, Lovenjoel (Belgium)
Assigned to K.U. Leuven Research & Development, Leuven (Belgium)
Appl. No. 10/529,508 PCT Filed Sep. 26, 2003, PCT No. PCT/BE03/00164 § 371(c)(1), (2), (4) Date Jun. 27, 2005, PCT Pub. No. WO2004/029246, PCT Pub. Date Apr. 08, 2004.
Claims priority of application No. 0222361.8 (GB), filed on Sep. 26, 2002; and application No. 0224539.7 (GB), filed on Oct. 22, 2002.
Prior Publication US 2006/0275748 A1, Dec. 07, 2006
Int. Cl. A61K 39/385 (2006.01); A61K 39/21 (2006.01); G01N 33/53 (2006.01); C12Q 1/70 (2006.01); G01N 33/569 (2006.01)

U.S. Cl. 435—7.8  [435/5; 424/196.1; 424/207.1; 424/208.1]

9 Claims

1. A method of screening molecule(s) for their antiviral activity comprising the step of exposing said molecules to the protein Lens Epithelial Cell Derived Growth Factor (LEDGF/P75) or a fragment thereof, or a nucleic acid encoding said LEDGF/P75 or a fragment thereof and determining the ability of said molecule(s) to modulate the interaction of said protein LEDGF/P75 with a retroviral integrase.